NEW YORK, NY / ACCESS Newswire / September 17, 2025 / Every once in a while, an industry has its thunderbolt moment.
Icotrokinra demonstrated superior skin clearance at Weeks 16 and 24 compared to deucravacitinib and similar adverse event ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback